Meiji Seika Of Japan Signs Licensing Allergic Agent Agreement With Amalyte Pharmaceuticals
This article was originally published in PharmAsia News
Executive SummaryJapanese food and drug conglomerate Meiji Seika Kaisha June 8 signed a licensing agreement and granted worldwide, exclusive development and marketing rights for allergy agent ME3301 and its derivatives to San Francisco biotech Amalyte Pharmaceuticals. ME3301 is currently under Phase II development in Europe and Japan for asthma and allergic rhinitis, and Meiji Seika also studied the drug for inflammatory bowel disorders. Meiji Seika will receive upfront and milestone payments and royalties. In recent years, the company has consolidated business and centered on developing agents for infection and central nervous system disorders, and licensed out non-core agents. (Click here for more - Japanese language
You may also be interested in...
The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.